Rationale and design of a phase II study to evaluate prophylactic treatment of dacomitinib-induced dermatologic adverse events in epidermal growth factor receptor-mutated advanced non-small cell lung cancer (SPIRAL-Daco study)

Iwasaku, M; Uchino, J; Yamada, T; Chihara, Y; Shimamoto, T; Tamiya, N; Kaneko, Y; Kiyomi, F; Takayama, K

Uchino, J (reprint author), Kyoto Prefectural Univ Med, Dept Pulm Med, Kamigyo Ku, 465 Kajii Cho, Kyoto 6020857, Japan.

TRANSLATIONAL LUNG CANCER RESEARCH, 2019; 8 (4): 519

Abstract

Background: Dacomitinib is the first second-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) to significantly improve ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索